Fast Locator 2011-2012: Lonza - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fast Locator 2011-2012: Lonza



A HISTORY OF INNOVATION
In 1897, Lonza was founded on the banks of the river Lonza in the Swiss Alps by adventurous entrepreneurs. Today, Lonza continues to embody that pioneering spirit as a leading innovator and partner for the pharmaceutical, healthcare, nutrition, personal care, cosmetic, industrial biotech and life science industries.

PROVEN TRACK RECORD
For over 25 years, Lonza Custom Manufacturing has been helping emerging and large biotechnology and pharmaceutical companies improve and advance their products. Whether for clinical or commercial supply, Lonza’s complete set of development services, industry-leading manufacturing processes, and broad chemical and biotechnology platforms enable your products to reach their full potential.

EXTENSIVE CAPABILITIES & EXPERIENCE
Active pharmaceutical ingredients (APIs), highly potent APIs, advanced intermediates, fine chemicals, nutraceuticals, cosmeceuticals, antibody drug conjugates, peptides, vaccines, plasmid DNA, recombinant novel proteins, monoclonal antibodies, antibody fragments, cell-based therapeutics, research products and media services … Lonza has the know-how and experience to handle almost any pharmaceutical or biotechnology challenge, around the globe.


COMPLETE PROCESS R&D SERVICES:

  • AggreSolve Protein Aggregation Predictor
  • The GS Gene Expression System
  • XS Microbial Expression Technologies
  • Cell line construction
  • Strain design
  • Bio/catalyst design
  • Process development
  • Process scale-up
  • Process validation
  • Process transfer
  • Technology development
  • Regulatory support

WORLDWIDE, STATE-OF-THE-ART FACILITIES
North America: Portsmouth, NH; Hopkinton, MA; Walkersville, MD
Europe: Slough, UK; Kourim, CZ; Porrino, ES; Braine, BE; Verviers, BE
Asia: Nansha, CN; Singapore, SG


Contact:

Lonza
Muenchensteinerstr. 38
CH-4002 Basel
Switzerland
+41 61 316 8111
contact@lonza.com

Website:

www.lonza.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
22%
To all process for new products only
12%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search

Click here